interferon for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
TOGETHER interferon lambda NCT04727424		RCT	peginterferon	placebo	COVID 19 outpatients	NA	916/1020	conclusif	demonstrated 53 % decrease in Emergency room visit or hospitalization (PE) suggested 44 % decrease in hospitalization
Feld NCT04354259		RCT	peginterferon	placebo	COVID 19 outpatients	low	30/30	conclusif	demonstrated 3.1-fold increase in viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis